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OS and PFS are 64% (95%CI: 47-86%) and 49% (95%CI: 32-
73%), respectively. In vivo T cell-depletionwith alemtuzumab
was associated with a markedly reduced 2-year PFS (0% vs
64%, p¼0.008) (Figure 1). Conversely, a sIPI at transplantation
<1 was associated with a much improved 2-year PFS (65% vs
13%, p¼0.021) compared to higher sIPI values (Figure 2).
Similarly, 2-year OS was also signiﬁcantly reduced with
alemtuzumab (33% vs 74%, p¼0.016) and in patients with sIPI
1 (39% vs 76%, p¼0.036).
Conclusions: RIC allo-SCT is a feasible and effective strategy
in patients with relapsed and refractory mantle cell lym-
phoma. High sIPI and use of alemtuzumab in the condi-
tioning regimen are associated with markedly inferior PFS.
Higher risk disease and the likely loss of graft-versus-lym-
phomawith alemtuzumab predict likelihood of failure of RIC
allo-SCT in relapsed and refractory MCL patients.80
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The treatment of advanced refractory DLBCL remains a major
challenge. High dose therapy with autologous stem cell
transplant (HDT/ASCT) has a limited role only in chemo-
sensitive relapsed disease, with a curative potential of 25-
50%. No therapy has proven to be effective long-term for
advanced chemo-refractory DLBCL. Although allo-HCT has
curative potential, historically, the outcomes remain unsat-
isfactory due to high treatment related mortality (TRM) after
myeloablative conditioning (MAC), high relapse rate after
reduced-intensity conditioning (RIC) regimens and theconcern for a less potent graft-versus-lymphoma effect (GVL)
A total of 97 DLBCL patients (pts) [M64:F33] undergoing allo-
HCT at UM between 1996 and 2011 were retrospectively
evaluated. The median age was 52 yrs (range, 23-70). Sev-
enty-four pts (76%) received a MAC [CVB in 49 pts (50%),
FluBu4 in 13 pts (13%), others in 12 (12%)]; 23 pts received
RIC with FluBu2 (24%); 79 pts (81%) were 8/8 HLA-matched.
Only 18 pts (19%) had prior HDT/ASCT. Donor sources were
58 related, 6 mismatched (MM), and 39 unrelated, 12 MM.
Stem cell sources were peripheral blood in 89%, bone
marrow in 10% and cord blood in 1%. GVHD prophylaxis was
tacrolimus/ mini-methotrexate in 71 pts (73%), tacrolimus/
MMF in 16 pts (17%) and others in 10 pts (10%). Fifty-ﬁve pts
(57%) had chemo-sensitive disease at transplant; 22 pts
(23%) had transformed DLBCL.
With a median follow-up time of 12 months (range, 1.6-194),
the cumulative incidences of grade 2-4, grade 3-4 acute
GVHD, chronic GVHD, TRM, relapse, OS and PFS were not
statistically different between the MAC and RIC cohorts
(Table). Relapse rate remained high in both groups. Chemo-
sensitivity, donor source and type of DLBCL had no impact on
survival.
In summary, allogeneic HCT for advanced DLCBL is feasible,
with acceptable TRM. Although, relapse is a major issue, allo-
HCT provides these heavily pretreated pts with a platform to
combine the GVL effect with other strategies tomaximize the
potential of long-term disease-free survival.PEDIATRIC DISORDERS81
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Table 1
Total
Number of patients (n) 168
Male sex (%) 58
Age (years) 6.1 (0.2-22.7)
Starting day ATG (days before transplantation) 5 (1-19)
Diagnosis (%)
Malignancy 48
Immune deﬁciency 21
Bone marrow failure 8
Metabolic disease 13
Benign hematology 8
Stem cell source (%)
Bone marrow 39
Peripheral blood stem cells 10
Cordblood 47
Cordblood with haplo or cordblood 4
Event Free Survival (%) 57
Overall Survival (%) 67
Follow up (weeks) 130 (1-440)
Figure 1. Schematic representation of active Thymoglobulin concentrations
and CD3+ T-cell counts in blood versus time showing various PK-endpoints.
Figure 2. Kaplan-Meier survival analysis of 168 patients with a ﬁrst trans-
plantation without occurrence of IgG anti-ATG antibodies stratiﬁed according
to the cut-off level of post-HCT AUC 20 AU*day/L: low AUC is a predictor of
overall survival.
Figure 3. Post-HCT AUC of active Thymoglobulin of patients with (un)suc-
cessful T-cell reconstitution (black 0) and patients with GvHD  grade 2 (red I)
with a logistic regression depicting the chance of successful reconstitution
versus post-HCT AUC of active Thymoglobulin (black line) and the chance of
developing GvHD  grade 2 versus post-HCT AUC of active Thymoglobulin
(red line). Dashed line: 50% chance of event.
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Background: To prevent graft versus host disease (GvHD)
and rejection in unrelated hematopoietic cell trans-
plantation (HCT), children receive anti-thymocyte globulin
(ATG), in the conditioning regimen. The therapeutic win-
dow is critical as over-exposure results in delayed immune
reconstitution (IR) and under-exposure GvHD: both
causing signiﬁcant morbidity and mortality. As the optimal
exposure is unknown we studied the association between
active ATG (Thymoglobulin) exposure and outcomes as
a step towards an evidence based dosing regimen of
Thymoglobulin.
Methods: All pediatric patients transplanted between 2004
- 2012 receiving Thymoglobulin in the two study centers
were included. Only ﬁrst HCTs were included and patients
mounting IgG anti-ATG antibodies were excluded. Serum
active Thymoglobulin concentrations were quantiﬁed by
ﬂow cytometry investigating the binding to a T-cell line.
Different exposure related variables such as AUC (area un-
der the curve: ﬁg 1) were tested for their association with
the endpoints: event-free survival (EFS), overall survival
(OS), acute GvHD and T-cell reconstitution. AUC’s were
calculated using a validated population PK model. EFS was
deﬁned as being alive with engraftment without relapse of
disease. T-cell reconstitution was deﬁned as a CD3+ T-cell
count> 100 x106/L in two consecutive occasions within 100
days after HCT. aGvHD was classiﬁed using the Glucksberg
Figure 1. Cognitive development estimated by the cognitive status at HCT.
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were used.
Results: Pharmacokinetic and -dynamic data were available
from 196 pediatric HCT’s (Table 1); 28 were excluded due to
2nd/3rd HCT (13) or antibodies (15). Post-HCT exposures
correlates best with the endpoints. 5-year probability of OS
and EFS were higher in patients with a low (<20 AU*days/L)
post-HCT AUC (p<0.01: OS according to AUC in ﬁg 2).
Multivariate predictors for lower OS were high (>20
AU*days/L) post-HCT AUC (p¼0.024), mismatch donor
(p¼0,01) and malignancy (p¼0,007). In addition, low post-
HCT AUC of Thymoglobulin was associated successful T-cell
reconstitution (p<0.005) while incidence of aGvHD
increased (p¼0.01), although the absolute increase of prob-
ability of aGvHD is less relevant (ﬁg 3).
Conclusion: High (>20 AU*days/L) post-HCT exposure of
Thymoglobulin is associated with a lower OS and a lower
probability of successful IR. These results may contribute to
individualized dosing guidelines of Thymoglobulin in chil-
dren, aiming to improved survival.Figure 3. Height estimated by the obtained leukocyte IDUA enzyme level.
Figure 2. Occurrence of surgical intervention for cord compression estimated
by the obtained leukocyte IDUA enzyme level.82
Predictors of Long-Term Clinical Outcome in Hurler
Syndrome Patients after Successful Hematopoietic Cell
Transplantation: An International Study
Mieke Aldenhoven 1, Paul Orchard 2, Joanne Kurtzberg 3,
Robert Wynn 4, Anne O’Meara 5, Paul Veys 6, Alain Fischer 7,
Vassili Valayannopoulos 7, Benedicte Neven 7, Attilio Rovelli 8,
Vinod K. Prasad 3, Jakub Tolar 2, Elsa Shapiro 2, Simon Jones 4,
Rossella Parini 8, Marleen Renard 9, Victoria Bordon 10,
Michele Poe 11, Tom de Koning 12, Ed Wraith 4, Maria Escolar 11,
Jaap-Jan Boelens 13. 1University Medical Center Utrecht,
Utrecht, Netherlands; 2University of Minnesota, Minneapolis,
MN; 3Pediatric BMT Program, Duke University Medical Center,
Durham, NC; 4Royal Manchester Children’s Hospital,
Manchester, United Kingdom; 5Our Lady’s Hospital for Sick
Children, Dublin, Ireland; 6Great Ormond Street Hospital for
Children, London, United Kingdom; 7Hôpital Universitaire
Necker-Enfants Malades, Paris, France; 8San Gerardo University
Hospital, Monza, Italy; 9University Hospital Gasthuisberg,
Leuven, Belgium; 10Ghent University Hospital, Ghent, Belgium;
11University of Pittsburgh, Pittsburgh, PA; 12University Medical
Center Groningen, Groningen, Netherlands; 13Blood and
Marrow Transplantation Program, University Medical Center
Utrecht, Utrecht, Netherlands
Objectives: Hurler syndrome (HS), the most severe pheno-
type of Mucopolysaccharidosis type I, is caused by a deﬁ-
ciency of the lysosomal enzyme alpha-L-iduronidase (IDUA).
HS is clinically characterized by a progressive and ultimately
fatal multi-system deterioration with involvement of the
central nervous system (CNS). At present, hematopoietic cell
transplantation (HCT) is the only treatment able to prevent
disease progression in the CNS and therefore considered the
treatment of choice in HS. However, there is a lack of long-
term follow-up data on successfully transplanted HS pa-
tients as well as the factors inﬂuencing them. Therefore, this
international multicenter study was initiated to identify
predictors of the long-term outcome of successfully trans-
planted HS patients worldwide.
Methods: Alive and engrafted HS patients with at least 3
years follow-up after HCT were retrospectively evaluated. The
main endpoint included the neurodevelopmental outcome;
secondary endpoints included the growth, neurologic, ortho-
pedic, cardiac, respiratory, ophthalmologic, audiologic andendocrinologic outcome. The inﬂuence of patient, donor, and
transplantation-related variables on these endpoints was
analyzed using multivariate Cox proportional hazards, logistic
regression, and linear mixed models.
Results: 197 HS patients from 10 transplantation centers
within Europe and the United States were included. This is
estimated to represent about 70% of the HS patients suc-
cessfully transplanted worldwide till 2008. Patients had a
